Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Divi's Laboratories Limited engages in the manufacture and sale of generic active pharmaceutical ingredients (APIs), intermediates, and nutraceuticals in India, North America, Asia, Europe, and internationally. The company also undertakes custom synthesis contract manufacturing services of APIs and intermediates; and supplies a range of carotenoids, such as beta carotene, astaxanthin, lycopene, and canthaxanthin, as well as other finished forms, including lutein, and vitamins to food, dietary supplement, and feed manufacturers industries. It also exports its products. The company was formerly known as Divi's Research Center and changed its name to Divi's Laboratories Limited in 1994. Divi's Laboratories Limited was incorporated in 1990 and is based in Hyderabad, India.

Revenue projections:

Revenue projections for DIVISLAB
Revenue projections for DIVISLAB

Investors may react cautiously to news that DIVISLAB's revenues are forecasted to be lower than last year's. Such declines are likely to have a negative effect on the company's bottom line, which can lead to concerns about profitability and hinder investor confidence in the company's future performance.

Financial Ratios:

currentRatio 6.943000
forwardPE 54.503483
debtToEquity 0.027000
earningsGrowth 0.231000
revenueGrowth 0.122000
grossMargins 0.602030
operatingMargins 0.301350
trailingEps 82.280000
forwardEps 56.300000

DIVISLAB's current ratio of 6.943 reflects its strong liquidity position. The company has enough cash reserves and current assets to service its short-term debt obligations, signaling that DIVISLAB is financially well-prepared to meet its liabilities without difficulty.
With DIVISLAB's forward PE being too high, further price appreciation may be limited, and a correction could occur. This valuation metric signals potential overvaluation, and investors should analyze it carefully along with other fundamentals to make informed decisions.
DIVISLAB's positive earnings and revenue growth signal that the company is expected to expand its business. This healthy financial trend reflects an optimistic outlook, suggesting continued growth in both sales and profits for DIVISLAB.
DIVISLAB's positive gross and operating margins reflect strong financial performance. These metrics indicate that the company is efficiently managing its operations and generating healthy profits, contributing to a solid financial position.
With forward EPS less than trailing EPS, DIVISLAB is expected to see reduced earnings. This suggests the company may face profitability challenges in the current financial year compared to the previous one.

Price projections:

Price projections for DIVISLAB
Price projections for DIVISLAB

Over time, price projections for DIVISLAB have gradually risen, signaling growing optimism about the company's future. This upward revision reflects increasing confidence in DIVISLAB's ability to achieve strong financial results.

Insider Transactions:

Insider Transactions for DIVISLAB
Insider Transactions for DIVISLAB


28 DIVISLAB transactions were recorded, when the market price was 5341.514317103794.2 purchases of DIVISLAB stock were recorded, with market price of 5854.875 per share.There is no clear trend from the insider transactions, providing limited insights into whether these actions reflect growth or decline.

Recommendation changes over time:

Recommendations trend for DIVISLAB
Recommendations trend for DIVISLAB


DIVISLAB has been receiving a buy bias from analysts, signaling strong confidence in the stock's future performance. This positive outlook might drive investors to view DIVISLAB as an attractive option for their portfolios, positioning the company as a stable and profitable investment choice.